ProMIS Neurosciences Inc.: insider trades · United States · SEC (Form 4)

About ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. (NASDAQ: PMN, United States) is a clinical-stage biotechnology company focused on discovering and developing therapeutic antibodies and vaccines that target misfolded proteins implicated in neurodegenerative disease. For investors, the company should be viewed as a pipeline-driven biotech rather than a revenue-generating commercial platform, meaning valuation is highly sensitive to clinical readouts, regulatory progress, and financing milestones. ProMIS was incorporated in 2004 and has long been associated with Toronto, Ontario, while also maintaining operations in Cambridge, Massachusetts. That dual footprint gives the company a North American operating base with direct access to the U.S. biotech and capital markets ecosystem. ([promisneurosciences.com](https://www.promisneurosciences.com/investors/sec-filings/content/0001558370-24-005785/pmn-20231231xars.pdf?utm_source=openai)) Strategically, ProMIS is built around a proprietary approach to toxic oligomers, especially in Alzheimer’s disease, while extending the same scientific logic to other neurodegenerative disorders. Its lead asset is PMN310, a humanized antibody designed to selectively bind toxic beta-amyloid oligomers in Alzheimer’s disease. The pipeline also includes PMN311, an Alzheimer’s vaccine candidate, and PMN442, now the lead candidate for Parkinson’s disease and other synucleinopathies. Historically, the company has also referenced programs in ALS and multiple system atrophy. The common thread across the portfolio is a selective-targeting philosophy aimed at attacking the most pathogenic protein species while potentially limiting off-target activity. ([promisneurosciences.com](https://www.promisneurosciences.com/news-media/press-releases/detail/251/promis-neurosciences-announces-second-quarter-2025?utm_source=openai)) From a competitive standpoint, ProMIS operates in a crowded and scientifically demanding segment dominated by large pharmaceutical companies and specialist biotech peers pursuing Alzheimer’s and Parkinson’s therapies. Its differentiation is primarily based on its platform claim: an antibody and vaccine strategy focused on toxic oligomer species, which could be meaningful if confirmed in human studies. However, as with most small-cap biotech names listed on the NASDAQ, the investment case remains dependent on a small number of binary catalysts and the company’s ability to fund development. Recent company updates indicate that the PRECISE-AD Phase 1b study of PMN310 is fully enrolled, with six-month assessments and interim analysis expected in 2026 and later top-line data anticipated around early 2027. ([nasdaq.com](https://www.nasdaq.com/press-release/promis-neurosciences-announces-full-year-2025-financial-results-and-provides?utm_source=openai)) Recent highlights are important for the market narrative. ProMIS selected PMN442 as its lead candidate for Parkinson’s disease and other synucleinopathies, advanced PMN310 through early clinical development, and announced a private placement financing in January 2026 that could total up to approximately $175 million to extend its cash runway and support key clinical milestones. The company also reported first-quarter 2026 financial results in May 2026, confirming continued execution on its clinical programs. For U.S. and international investors alike, PMN is best characterized as a high-risk, high-upside clinical-stage neuroscience biotech quoted on the NASDAQ in the United States, with meaningful upside if its targeted protein approach translates into human efficacy. ([promisneurosciences.com](https://www.promisneurosciences.com/investors/news-events/press-releases/detail/261/promis-neurosciences-announces-up-to-175-million-private?utm_source=openai))